Quinuclidinyl Benzilate

Quinuclidinyl Benzilate

SCHEMBL241173

O=C(O[C@H]1CN2CCC1CC2)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 1.00
CHRM1 P11229 4/20 1.00
CHRM3 P20309 4/20 1.00
CHRM4 P08173 1/20 1.00
CHRM5 P08912 1/20 1.00
ALDH1A1 P00352 1/20 0.69
TSHR P16473 1/20 0.69
MAPK1 P28482 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinuclidinyl Benzilate SCHEMBL59698 1.00 CHRM2 (1.00) CHRM2CHRM1CHRM3CHRM4CHRM5
Quinuclidinyl Benzilate SCHEMBL29433215 0.99 CHRM2 (0.97) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL9848226 0.93 CHRM2 (0.86) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL9145154 0.93 CHRM2 (0.86) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL9146007 0.93 CHRM2 (0.86) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL9148881 0.93 CHRM2 (0.86) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL9146124 0.93 CHRM2 (0.86) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL10814164 0.93 CHRM2 (0.86) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL8529194 0.93 CHRM2 (0.86) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL10817618 0.93 CHRM2 (0.86) CHRM2CHRM1CHRM3CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240316023-A1 BENEDIN, PIPERIDINE, 2-BENZHYDRYL-3-HYDROXY-N-METHYL-, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR USE IN TREATING KLEINE-LEVIN SYNDROME NLS PHARMACEUTICS AG (CH) 2024-09-26 US disclosed
CN-117956994-A Bei Niding, piperidine, 2-benzhydryl-3-hydroxy-N-methyl-, hydrochloride and derivatives thereof for the treatment of clariant-levensembles NLS制药股份公司 2024-04-30 CN disclosed
EP-1633703-B1 ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF PERKINELMER LAS INC (US) 2018-12-26 EP disclosed
US-8987501-B2 Isotopically labeled chemically stable reagents and process for the synthesis thereof PERKINELMER HEALTH SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130030184-A1 ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF PERKINELMER HEALTH SCIENCES, INC. (US) 2013-01-31 US disclosed
US-8329934-B2 Isotopically labeled chemically stable reagents and process for the synthesis thereof PERKINELMER HEALTH SCIENCES, INC. (US) 2012-12-11 US disclosed
US-8168654-B2 Quinuclidine derivatives binding to mucarinic M3 receptors NOVARTIS AG (CH) 2012-05-01 US disclosed
US-20120004413-A1 ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF PERKINELMER HEALTH SCIENCES, INC. (US) 2012-01-05 US disclosed
US-8058464-B2 Isotopically labeled chemically stable reagents and process for the synthesis thereof PERKINELMER HEALTH SCIENCES, INC. (US) 2011-11-15 US disclosed
US-20100041887-A1 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS COLLINGWOOD STEPHEN PAUL 2010-02-18 US disclosed
EP-1631569-B1 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS NOVARTIS AG (CH) 2009-08-26 EP disclosed
US-20070060563-A1 Quinuclidine derivatives binding to mucarinic m3 receptors NOVARTIS AG (CH) 2007-03-15 US disclosed
EP-1633703-A4 ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF PERKINELMER LAS INC (US) 2006-11-15 EP disclosed
US-20060205953-A1 Isotopically labeled chemically stable reagents and process for the synthesis thereof PERKIN ELMER LAS, INC. (US) 2006-09-14 US disclosed
EP-1633703-A2 ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF Perkinelmer Las, Inc. (US) 2006-03-15 EP disclosed
EP-1631569-A2 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS Novartis AG (CH) 2006-03-08 EP disclosed
WO-2004108636-A2 ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF PERKINELMER LAS, INC. (US) 2004-12-16 WO disclosed
WO-2004096800-A2 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS NOVARTIS AG (CH) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060563-A1 Quinuclidine derivatives binding to mucarinic m3 receptors CHRM3, CHRM2, CHRM1 CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885
US-20240316023-A1 BENEDIN, PIPERIDINE, 2-BENZHYDRYL-3-HYDROXY-N-METHYL-, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR USE IN TREATING KLEINE-LEVIN SYNDROME GABBR2, GABBR1, GABRB1 CHRM2 950/4885CHRM1 887/4885CHRM3 1843/4885
US-20130030184-A1 ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF ALKBH2, ALKBH3, ALKBH1 CHRM2 1097/4885CHRM1 515/4885CHRM3 458/4885
US-20120004413-A1 ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF HBG2, ALKBH2, ACVR2B CHRM2 830/4885CHRM1 415/4885CHRM3 826/4885
US-20100041887-A1 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS CHRM3, CHRM2, CHRM1 CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885
US-20060205953-A1 Isotopically labeled chemically stable reagents and process for the synthesis thereof MRPS23, MRPS22, IPO11 CHRM2 1531/4885CHRM1 408/4885CHRM3 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.